Asahi Y, Kamiyama T, Kakisaka T, Orimo T, Shimada S, Nagatsu A, Aiyama T, Sakamoto Y, Kamachi H, Taketomi A. Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(10): 1245-1257 [PMID: 34754392 DOI: 10.4240/wjgs.v13.i10.1245]
Corresponding Author of This Article
Yoh Asahi, MD, PhD, Surgeon, Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 15, Nishi 7, Sapporo 060-8638, Hokkaido, Japan. yoh-hibana@yk2.so-net.ne.jp
Research Domain of This Article
Surgery
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Hirofumi Kamachi, Akinobu Taketomi, Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Hokkaido, Japan
Author contributions: Asahi Y analyzed and interpreted the patient data, was involved in the data acquisition, made substantial contributions to the study conception and design, and was a major contributor during the writing of the manuscript; Kamiyama T participated in drafting and critically revising the article; Kakisaka T, Orimo T, Shimada S, Nagatsu A, Aiyama T, Sakamoto Y and Kamachi H revised the draft manuscript by adding intellectual insights and providing critical advice; Taketomi A provided critical comments to improve the manuscript and gave final approval for its submission; all of the authors have read and approved the final manuscript.
Institutional review board statement: This research was approved by the institutional review board of Hokkaido University Hospital.
Informed consent statement: Informed consent of patients was obtained in the form of opt-out on the web site of Hokkaido University Hospital.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yoh Asahi, MD, PhD, Surgeon, Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 15, Nishi 7, Sapporo 060-8638, Hokkaido, Japan. yoh-hibana@yk2.so-net.ne.jp
Received: April 19, 2021 Peer-review started: April 19, 2021 First decision: August 9, 2021 Revised: August 21, 2021 Accepted: September 14, 2021 Article in press: September 14, 2021 Published online: October 27, 2021
Core Tip
Core Tip: This was a retrospective study examining the outcomes of combination treatment with reduction hepatectomy and multidisciplinary postoperative treatment for advanced hepatocellular carcinoma (HCC). When reduction hepatectomy is performed for unresectable advanced HCC that is not indicated for curative hepatectomy, achieving postoperative complete remission (POCR) via postoperative multidisciplinary therapy is the key to success, with the 5-year overall survival rate and mean survival time for the POCR (+) group being 37.5% and 56.55 mo, respectively. To achieve POCR, reduction hepatectomy should be performed with the aim of reducing the number of tumors in the remnant liver to ≤ 3. Even in cases in which POCR is not achieved, tyrosine kinase inhibitor treatment might improve the prognosis of advanced HCC after reduction hepatectomy.
